NCT03634982: Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors

NCT03634982
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: KRAS+, RAF, NF1/2
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have RTK mutations, amplifications or rearrangements, KRASG12, BRAF Class 3, or NF1 LOF mutations to be eligible for the expansion phase
Exclusions: Patients with known or suspected leptomeningeal or brain metastases
https://ClinicalTrials.gov/show/NCT03634982

Comments are closed.

Up ↑